Novel Mitochondria-Targeted Asymmetric Heptamethine Cyanine Dye for Cancer Targeted NIR Imaging and Potent Necrosis and Senescence Induction with Prolonged Retention
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02879 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Siyi Zeng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-So…. Hauptthemen laut MEDLINE: Mitochondria, Carbocyanines, Antineoplastic Agents, Fluorescent Dyes. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Sichuan University, Science and Technology Department of Sichuan Province, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Developing small molecules that inherently integrate highly tumor-targeted near-infrared fluorescence (NIRF) imaging with potent therapeutic effects remains challenging in anticancer theranostics. Here, we synthesized and characterized a series of heptamethine cyanine PSs with symmetric and asymmetric structures. Among them, we first discovered that asymmetric structures significantly enhanced tumor targeting. Also, a novel mitochondria-targeted asymmetric compound 17 exhibited superior NIRF imaging capability, exceptional tumor selectivity (TNR = 8.54), and strong antitumor activity. Compound 17 selectively accumulates in mitochondria, driven by MMP, where it generates ROS, induces DNA damage, and triggers senescence, apoptosis, and necrosis. Its strong therapeutic efficacy was demonstrated across multiple models, including patient-derived xenograft (PDX), where it allowed precise tumor visualization, significantly suppressed tumor growth with a single administration, and showed no detectable toxicity. Notably, the single-dye small molecule 17 was retained in tumors for over 120 h, enabling prolonged imaging, targeted therapy, and drug delivery for integrated antitumor treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial T…
- Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of C…
- NHC Key Laboratory of Nuclear Technology Medical Transformation (Mianyang Central Hospital), Mianyang 621000, China.
- Sichuan Provincial Engineering Research Center of Nuclear Medical Equipment Translation and Application (Mianyang Central Hospital), Mianyang 621000, China.
ORCID-Profile: Tao Jia
Förderung
- Sichuan University
- Science and Technology Department of Sichuan Province
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Zeng, S., Liu, L., Cheng, Q., Chen, W., Wang, M., Wu, M., Wang, Z., Du, J., Xiang, R., Qi, Q., & Jia, T. (2025). Novel Mitochondria-Targeted Asymmetric Heptamethine Cyanine Dye for Cancer Targeted NIR Imaging and Potent Necrosis and Senescence Induction with Prolonged Retention. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02879
Vancouver
Zeng S, Liu L, Cheng Q, Chen W, Wang M, Wu M, et al. Novel Mitochondria-Targeted Asymmetric Heptamethine Cyanine Dye for Cancer Targeted NIR Imaging and Potent Necrosis and Senescence Induction with Prolonged Retention. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02879
BibTeX
@article{Zeng2025,
author = {Zeng, Siyi and Liu, Linxia and Cheng, Qi and Chen, Wanlei and Wang, Maolin and Wu, Mingxia and Wang, Zhu and Du, Junrong and Xiang, Run and Qi, Qingrong and Jia, Tao},
title = {Novel Mitochondria-Targeted Asymmetric Heptamethine Cyanine Dye for Cancer Targeted NIR Imaging and Potent Necrosis and Senescence Induction with Prolonged Retention},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02879}
}
EUVIMED